iRhythm Finds Its Groove at the Intersection of Cardiology and AI
iRhythm Technologies has the distinct feature of being at the intersection of some of the hottest markets in medtech â cardiology, wearables, and artificial intelligence. The San Francisco-based company has developed, the Zio Patch XT, a wearable technology to monitor heart rate activity for up to 14 days and is set to present at the 37th Annual J.P. Morgan Healthcare Conference this week.
Tim King, iRhythmâs president and CEO spoke to MD+DI ahead of the companyâs presentation about the company's success and its goals going forward.
âThe tool of choice for the last 50 or 60 years has been the Holter monitor,â King told MD+DI. âIn reality it was not a really very good test and most physicians would admit to that. Its diagnostic yield is about 25% at best â meaning in one out of four patients something will be found. Whether or not itâs clinically actionable or significant is the problem. iRhythm studied this problem for quite a while and thought that the intersection of the wearable biosensor ⦠combined with massive computing power [was a solution]. So, if you could combine all this data on this device and curate this data for physicians into a small actual report, then you could kind of revolutionize how cardiac arrhythmias are diagnosed.â
Hence the Zio Patch was developed. The technology received...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Digital Health Source Type: news
More News: Arrhythmia | Atrial Fibrillation | Cardiac Arrhythmia | Cardiology | Cardiovascular | Conferences | Electrocardiogram | Heart | Heart Transplant | Learning | Patient Communication | Study | Universities & Medical Training